Marina Viñeta Paramo

Dr. Marina Viñeta Paramo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in eClinicalMedicine
Verified
Journal Article
Open access
BABahaa Abu-Raya
Bahaa Abu-Raya
MPMarina Viñeta Paramo
Marina Viñeta Paramo
FRFrederic Reicherz
Frederic Reicherz
PLPascal Michel Lavoie
Pascal Michel Lavoie
The coronavirus disease 2019 (COVID-19) pandemic has drastically perturbed the epidemiology of Respiratory Syncytial Virus (RSV) respiratory tract infections in children. The reasons for this are not clear. In this article, we review the current literature and critically discuss the different theories to explain why the epidemiology of RSV has changed during the COVID-19 pandemic. Proposed mechanisms include decreased viral immunity in vulnerable age groups caused by the prolonged lack of RSV circulation early in the pandemic, potential Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)-induced immune dysregulation, viral interactions between SARS-CoV-2 and RSV, and modifications in health-seeking behaviors as well as heath systems factors. Research in viral genomics and phylogeny, and more robust immunology research is needed to guide RSV prevention and health care resource planning.

30 August 2023 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
MPMarina Viñeta Paramo
Marina Viñeta Paramo
LNLilian P.L. Ngo
Lilian P.L. Ngo
BABahaa Abu-Raya
Bahaa Abu-Raya
FRFrederic Reicherz
Frederic Reicherz
RXRui Yang Xu
Rui Yang Xu
PLPascal Lavoie
Pascal Lavoie
The COVID-19 pandemic has perturbed the seasonality of respiratory syncytial virus (RSV) infections. However, we lack data on how this impacted the severity of paediatric RSV cases. The objective of this study was to describe the clinical severity of RSV cases before, during and after pandemic measures in British Columbia (BC), Canada. Retrospective study of RSV cases from September 1st, 2017 to May 15th, 2023, with a review of RSV outcomes in children below 18 years old at BC's paediatric hospital. Temporal changes in RSV cases and hospitalisations were quantified using interrupted time series. BC experienced only 11 RSV cases (from 95,266 tests) between September 2020 and August 2021. This was followed by a resurgence of 9,529 RSV cases (219,566 tests [4.3% positive tests]) in 2021–22 and 8,215 cases (124,449 tests [6.6% positive tests]) in 2022–23, increased compared to 1,750 cases (48,664 tests [3.6% positive tests]) per corresponding yearly period in 2017–20. From September 2017 to May 2023, the median age of children with RSV at BC Children's Hospital increased from 8.7 [IQR: 2.0–26.0] to 19.6 [3.9–43.7] months per yearly period. More children were hospitalised in 2022–23 (n = 360), compared to 2017–20 (n = 168 per period) and 2021–22 (n = 172). However, we detected no increase in hospitalisations or ICU admissions in children born prematurely or with chronic cardiorespiratory conditions. The increased detection of symptomatic RSV cases in older children in 2021–22 and increased RSV-related hospitalisations in 2022–23 suggest a gradual increase in the pool of immunologically vulnerable children due to a prolonged lack of viral exposure. 10.13039/501100000023 Government of Canada via its COVID-19 Immunity Task Force.

18 March 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
FRFrederic Reicherz
Frederic Reicherz
MPMarina Viñeta Paramo
Marina Viñeta Paramo
JBJeffrey N Bone
Jeffrey N Bone
ALAlexanne Lavoie
Alexanne Lavoie
SLSirui Li
Sirui Li
PLPascal Lavoie
Pascal Lavoie
Longitudinal measurements of respiratory syncytial virus (RSV) immunity over 4 winter seasons reveal that viral neutralization titers, RSV prefusion F protein (pre-F)–specific immunoglobulin M and immunoglobulin G (IgG) levels, and RSV antibody–dependent cellular phagocytosis function gradually returned to prepandemic levels in female healthcare and school workers of childbearing age after 2 winter seasons, following the resurgence of RSV cases in the Vancouver metropolitan region (British Columbia, Canada). In contrast, pre-F IgG avidity profiles remained unchanged. These findings support the notion that repeated viral infections are necessary to maintain high RSV antibody levels in the population.

28 April 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MPMarina Viñeta Paramo
Marina Viñeta Paramo
MKMarilou Kiely
Marilou Kiely
LVLouis Valiquette
Louis Valiquette
MMMatthew P. Muller
Matthew P. Muller
AMAllison McGeer
Allison McGeer
JBJulie A. Bettinger
Julie A. Bettinger
Although clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration. Post-licensure, active, safety surveillance was conducted during the 2024-25 viral season in Canada, using parent-completed questionnaires distributed 8 days after immunization. Parents or caregivers of 1,559 children completed the survey. A third (454/1,559) of children had received nirsevimab co-administered with routine vaccines. Local injection-site reactions were reported in 140 children (9.0%), 79/454 (17.4%, [95%CI: 14.2-21.3]) when nirsevimab was co-administered and 61/1,105 (5.5% [95%CI: 4.3-7.1]) when nirsevimab was given alone. Injection-site reactions extending beyond the closest joint were uncommon (6/1,559, 0.4%). Health events that prevented daily activities or required healthcare consultation were reported in 38/1,105 (3.4%) cases with nirsevimab administered alone and 19/454 (4.2%) with nirsevimab co-administered. The most reported symptoms were rhinorrhea: 1.8%, cough: 1.7%, feeding/eating changes: 1.6%, fever: 1.6% and diarrhea or change in bowel habits: 1.5%. Rash occurred in 10 children (0.6%). No cases of anaphylaxis were reported. Overall, in this study nirsevimab was well tolerated, with low incidence of health events within seven days of immunization. Results after co-administration support the incorporation of nirsevimab into the routine vaccination schedule. Documenting parent-reported outcomes in post-licensure settings expands the safety data obtained from clinical trials and offers transparent, timely additional reassuring data to enhance parental confidence in RSV antibody interventions.

22 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SLSally J Lawrence
Sally J Lawrence
MPMarina Viñeta Paramo
Marina Viñeta Paramo
FRFrederic Reicherz
Frederic Reicherz
JBJeffrey N. Bone
Jeffrey N. Bone
ZSZahra Jama Hussein Shire
Zahra Jama Hussein Shire
KJKevan Jacobson
Kevan Jacobson
Background/Objectives: Severe acute respiratory syndrome (SARS-CoV-2) has had a profound global impact and continues to represent a health challenge worldwide. The durability of SARS-CoV-2 vaccine responses in pediatric inflammatory bowel disease (PIBD) patients receiving biologic therapies is unknown. This study aimed to quantify SARS-CoV-2 antibody responses post vaccination in these immunosuppressed patients over 12 months. Methods: Prospective study comparing antibody responses against SARS-CoV-2 spike protein at 1, 3, 6, and 12 months in PIBD patients aged 5–18 years treated with anti-tumor necrosis factor alpha (anti-TNF) therapies with or without an immunomodulator (IM) versus vedolizumab. Results: Between 1 May 2021 and 1 May 2022, 194 participants on anti-TNF monotherapy (n = 78), anti-TNF with IM (n = 83), vedolizumab (n = 15), and steroids (n = 18) were recruited. Anti-SARS-CoV-2 spike levels increased after the first vaccine and were further boosted 1 month after the second dose. Linear mixed-effects modelling showed antibody waning over time (effect difference −2509 IgG AU/mL per week [95%CI: −4998–−20, p = 0.048]), counterbalanced by booster doses (effect difference 184,138 IgG AU/mL per additional vaccine dose [95%CI: 138,342–229,934, p < 0.001]). Receiving anti-TNF therapy contributed to reduced antibody responses compared to vedolizumab (anti-TNF monotherapy effect difference: −212,640 [95%CI: −336,928–−88,351] p = 0.001; anti-TNF with IM: −151,880 [95%CI: −277,309–−26,451] p = 0.018). Seroconversion and breakthrough infection rates were similar between groups, and all infections were mild, without hospitalizations. Conclusions: Although SARS-CoV-2 antibody responses were attenuated in PIBD patients receiving anti-TNF therapy compared with vedolizumab, this did not impact protection, as seroconversion and breakthrough infection rates were similar, with no hospitalizations. These data reinforce the importance of updating vaccines and, in particular, SARS-CoV-2 vaccines in immunosuppressed PIBD patients on advanced therapies.

19 April 2026 in Journal of Clinical Virology
Verified
Journal Article
Open access
XDXiaoqing Dang
Xiaoqing Dang
JSJacob Shew
Jacob Shew
MPMarina Viñeta Paramo
Marina Viñeta Paramo
GSGraham Sinclair
Graham Sinclair
SLSirui Li
Sirui Li
PLPascal Lavoie
Pascal Lavoie
Respiratory syncytial virus (RSV) is the leading cause of respiratory infection in young children. Although passive immunization strategies are available for infants, the relationship between population immunity and epidemic intensity remains poorly understood. Measuring maternally derived RSV antibodies in newborns could provide a scalable sentinel approach to monitor population immunity. To demonstrate the feasibility of using residual newborn dried blood spots (NDBS), collected universally, to quantify population-level RSV antibody immunity at birth. We developed a method to quantify RSV antibody levels and function using residual NDBS from the British Columbia Newborn Screening Program. Assay performance and stability were first evaluated using adult dried blood spot (DBS) and serum controls, then applied to two NDBS sets. In adult DBS, IgG against RSV pre-fusion (pre-F) protein was stable for at least 30 days and ⁓20-fold lower than corresponding sera. In NDBS, pre-F IgG levels remained stable for 140 days at room temperature, correlated with viral neutralization titers (ρ=0.64, p < 0.0001; N = 159), and showed antigen specificity through competitive blocking with soluble post-F protein across multiple RSV antigens (pre-F, post-F, N, Ga, Gb). ⁓42% of samples were below the lower limit of quantification. RSV antibody immunity can be quantified from residual NDBS. This scalable approach enables population-level surveillance of RSV immunity and supports large-scale studies of seasonal RSV epidemiology and correlates of protection across regions.